Among patients with relapsed multiple myeloma, treatment with the investigational drug elotuzumab plus Revlimid® (lenalidomide) and low-dose dexamethasone resulted in high response rates. The results of this Phase II clinical trial were presented at the 2011 annual meeting of the American Society of Clinical Oncology.
Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of the body’s immune system. Patients with multiple myeloma have increased numbers of abnormal plasma cells that may produce increased quantities of dysfunctional antibodies detectable in the blood and/or urine.
Elotuzumab is an investigational drug that binds to a protein (the CS1 glycoprotein) that is commonly found on myeloma cells and rarely found on normal cells. This treatment allows the immune system to selectively kill myeloma cells.
To evaluate elotuzumab in the treatment of relapsed multiple myeloma, researchers conducted a Phase II clinical trial among 98 patients. Study participants were treated with one of two doses of elotuzumab in addition to Revlimid and low-dose dexamethasone.
- Overall, 82% of patients responded to treatment. The lower dose of elotuzumab produced a better response rate than the higher dose of elotuzumab.
- Serious side effects of the combined treatment regimen included low blood cell counts.
These results suggest that elotuzumab is active against relapsed multiple myeloma. A Phase III clinical trial of this treatment combination is now underway.
Reference: Richardson PGG, Moreau P, Jakubowiak AJ et al. Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: a randomized phase II study. Paper presented at: 2011 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2011; Chicago, IL. Abstract 8014.
Copyright © 2018 CancerConnect. All Rights Reserved.